Drug Trial Radar · NCT04130516
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Oct 21, 2019
Primary completion
Jun 30, 2026
Study completion Aug 15, 2026
Sponsor
- Lead sponsor
- Linnaeus Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Oct 17, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and in combination with pembrolizumab. The study will include a dose escalation phase, a dose expansion phase, and phase 2A cohorts. Up to 200 patients will be accrued for this study. Up to 15 study sites in the United States will participate in the study.
Conditions
- Solid Tumor, Adult
Interventions
LNS8801 -Small molecule, orally bioavailable, selective agonist of GPERDrug
LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER
Pembrolizumab - anti-PD-1 antibodyBiological
pembrolizumab- anti-PD-1 antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events observed for LNS8801 dosed alone and in combination with pembrolizumabTime frame: Duration of study, approximately 24 months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
Yale Cancer Center
New Haven, Connecticut
Massachusetts General Hospital
Boston, Massachusetts
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico
Columbia University Herbert Irving Comprehensive Cancer Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
University of Pennsylvania
Philadelphia, Pennsylvania
Thomas Jefferson University, Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania
MD Anderson Cancer Center
Houston, Texas
The START Center for Cancer Care
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.